Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation
I'm PortAI, I can summarize articles.
Candel Therapeutics Inc. has released a corporate presentation showcasing advances in immune-based cancer therapies, highlighting positive results for CAN-2409 in various cancer trials. The company reports a strong financial position with $87 million in cash and a $130 million term loan facility. Precommercialization activities for CAN-2409 are underway, with key milestones anticipated for 2025-2026, including updated clinical results and new phase 3 trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments